We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$585M
Cap. Flow %
-10.08%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC
BeOne Medicines Ltd
ONC
+$13M
4
BLUE
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.32%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMTX
101
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.41M 0.02%
234,493
– –
ATYR
102
aTyr Pharma
ATYR
$54.2M
$1.26M 0.02%
+17,857
New +$827K
IBRX icon
103
ImmunityBio
IBRX
$8.11B
$1.23M 0.02%
225,000
– –
ARGX icon
104
argenx
ARGX
$53.6B
$1.23M 0.02%
+54,337
New +$1.13M
IMDX
105
Insight Molecular Diagnostics
IMDX
$121M
$1.13M 0.02%
7,500
– –
CRBP icon
106
Corbus Pharmaceuticals
CRBP
$195M
$1.07M 0.02%
5,000
-3,333
-40% -$652K
KRYS icon
107
Krystal Biotech
KRYS
$9.72B
$997K 0.02%
+100,000
New +$1.01M
ARAV
108
DELISTED
Aravive, Inc. Common Stock
ARAV
$980K 0.02%
66,667
+8,334
+14% +$841K
VRDN icon
109
Viridian Therapeutics
VRDN
$2.49B
$915K 0.02%
+6,667
New +$1.12M
NVAX icon
110
Novavax
NVAX
$1.34B
$570K 0.01%
25,000
– –
XENE icon
111
Xenon Pharmaceuticals
XENE
$6.21B
$443K 0.01%
150,000
– –
ABBV icon
112
CALL
AbbVie
ABBV
$443B
– –
-500,000
Closed -$36.3M
AGIO icon
113
CALL
Agios Pharmaceuticals
AGIO
$2B
– –
-100,000
Closed -$5.14M
FCX icon
114
Freeport-McMoran
FCX
$93.6B
– –
-250,000
Closed -$3M
GS icon
115
Goldman Sachs
GS
$304B
– –
-100,000
Closed -$22.6M
IONS icon
116
Ionis Pharmaceuticals
IONS
$9.28B
– –
-135,000
Closed -$6.87M
MET icon
117
MetLife
MET
$61.9B
– –
-112,200
Closed -$5.46M
MSFT icon
118
CALL
Microsoft
MSFT
$3.69T
– –
-1,000,000
Closed -$68.9M
SRPT icon
119
CALL
Sarepta Therapeutics
SRPT
$1.95B
– –
-100,000
Closed -$3.37M
ZTO icon
120
ZTO Express
ZTO
$17.4B
– –
-500,000
Closed -$6.98M
SGEN
121
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-75,000
Closed -$3.84M
ATH
122
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
– –
-200,000
Closed -$9.92M
ALXN
123
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-20,900
Closed -$2.54M
ALXN
124
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-100,000
Closed -$12.2M
AIMT
125
DELISTED
Aimmune Therapeutics
AIMT
– –
-100,000
Closed -$2.06M
2 3 4
5
6

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group withdrew a net $585M in Q3 2017, closing 17 positions and reducing 35 holdings. Its most notable exit was Goldman Sachs, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Artal Group opened a new position in Achillion Pharmaceuticals worth $4.49M.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.